UBE2L6 Antibody
Description
Viral Replication Mechanisms
-
Senecavirus A (SVA): UBE2L6 promotes SVA replication by polyubiquitinating the viral 3D protein at lysine residues K169 and K321, enhancing its stability. Knockout of UBE2L6 reduces viral replication by 60–80% .
-
HIV-1: UBE2L6 inhibits HIV-1 virion release by >65%, an effect counteracted by the viral protein Vpu .
Cancer Biology
-
Acute Promyelocytic Leukemia (APL): UBE2L6 is induced 180-fold during all-trans retinoic acid (ATRA)-driven differentiation of NB4 cells. Knockdown impedes neutrophil differentiation, linking UBE2L6 to granulocytic maturation .
-
Esophageal Cancer: Depletion of UBE2L6 or ISG15 increases autophagic flux, enhancing chemosensitivity to 5-fluorouracil and rapamycin .
-
Ovarian Cancer: High UBE2L6 expression correlates with platinum resistance (p < 0.001) and shorter progression-free survival (median 11.1 vs. 31.4 months in UBE2L6-negative tumors) .
-
Melanoma: UBE2L6 mediates EZH2 ubiquitination via UHRF1/UBR4, regulating melanin synthesis and tumor progression .
Clinical and Therapeutic Implications
-
Biomarker Potential: UBE2L6 and ABCB6 co-expression predicts platinum resistance in serous ovarian carcinoma (r = 0.673, p < 0.001) .
-
Therapeutic Targeting: Inhibiting UBE2L6 in SVA-infected cells reduces viral load, suggesting antiviral applications . Conversely, enhancing UBE2L6 activity could counteract chemoresistance in cancers like melanoma .
Experimental Applications
-
Western Blot: Optimal dilutions range from 1:1,000 to 1:3,000, with recommended starting points at 1:2,000 .
-
Immunohistochemistry: Effective in paraffin-embedded tissues (e.g., human kidney, uterus) at 1:50–1:100 dilutions after citrate buffer antigen retrieval .
-
Functional Studies: Used to validate UBE2L6’s enzymatic role in ubiquitination cascades, particularly its cysteine-86-dependent activity .
Limitations and Considerations
Product Specs
Product Science Overview
Ubiquitin Conjugating Enzyme E2L 6 (UBE2L6), also known as UbcH8, is a member of the E2 ubiquitin-conjugating enzyme family. This enzyme plays a crucial role in the ubiquitination process, which is a cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves three classes of enzymes: ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin-protein ligases (E3s) .
UBE2L6 is highly similar in primary structure to the enzyme encoded by the UBE2L3 gene. It catalyzes the covalent attachment of ubiquitin or ISG15 to other proteins, functioning in the E6/E6-AP-induced ubiquitination of p53/TP53 and promoting the ubiquitination and subsequent proteasomal degradation of FLT3 . This enzyme is involved in various biological processes, including ISG15-protein conjugation, translesion synthesis, and the negative regulation of type I interferon production .
Mouse anti-human antibodies are secondary antibodies generated by immunizing mice with human immunoglobulins. These antibodies are affinity-purified and have well-characterized specificity for human immunoglobulins. They are commonly used in various detection systems, such as ELISA, Western Blot, Flow Cytometry, and Immunohistochemistry .
Secondary antibodies offer increased versatility and sensitivity through signal amplification, as multiple secondary antibodies can bind to a single primary antibody. They are generated by immunizing the host animal with a pooled population of immunoglobulins from the target species and can be further purified and modified to generate highly specific reagents .
The combination of UBE2L6 and mouse anti-human antibodies is significant in research and diagnostic applications. UBE2L6’s role in protein degradation and regulation of various cellular processes makes it a valuable target for studying diseases such as Alzheimer’s and Parkinson’s . Mouse anti-human antibodies, on the other hand, are essential tools in detecting and quantifying human proteins in various experimental setups.
